EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

COMPARISON OF CLINICAL EFFICACY OF TOFACITINIB VERSUS METHOTREXATE IN SEVERE ALOPECIA AREATA, ALOPECIA TOTALIS, AND ALOPECIA UNIVERSALIS: A RANDOMIZED CONTROLLED TRIAL

Hira Rehman, Ghafoor Ullah, Filza Ajmal, Tooba Rehman, Shahana Naseer, Marwah Rehman

Khyber Journal of Medical Sciences · 30.06.2026 · 19 (2)

DOI: 10.70520/kjms.v19i2.880 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Khyber Journal of Medical Sciences, online erschienen am 30.06.2026. Verfasst von Hira Rehman und 5 weiteren Autor:innen. Die Arbeit nennt 25 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To compare the 12-week clinical efficacy of oral tofacitinib with oral methotrexate in adults with severe alopecia areata, alopecia totalis, or alopecia universalis.

Methods

This open-label, parallel-group randomized controlled trial was conducted in the Department of Dermatology, Medical Teaching Institution-Hayatabad Medical Complex, Peshawar, from 8 October 2024 to 8 March 2025. Seventy-eight adults aged 18-60 years were enrolled by consecutive non-probability sampling and allocated by blocked randomization (1:1) to tofacitinib 10 mg twice daily or methotrexate 0.2-0.4 mg/kg once weekly for 12 weeks. Participants receiving systemic alopecia therapy, pregnant or lactating women, and patients with renal, hepatic, or pulmonary disease were excluded. The trial was open-label; no allocation-concealment procedure was documented in the supplied records. Severity of Alopecia Tool (SALT) scores were measured at baseline and week 12. Efficacy was defined as a >50% reduction in SALT score. Ethical approval (No. 2141; 23 September 2024) and written informed consent were obtained. The trial was retrospectively registered (NCT07406204).

Results

Baseline SALT scores were comparable between the tofacitinib and methotrexate groups (74.7 ± 9.5 vs 75.5 ± 8.7; p=0.68). At week 12, the mean SALT score was lower with tofacitinib (35.9 ± 11.2 vs 53.2 ± 9.5; p

Zitieren

APA

Rehman, H., Ullah, G., Ajmal, F., Rehman, T., Naseer, S., & Rehman, M. (2026). COMPARISON OF CLINICAL EFFICACY OF TOFACITINIB VERSUS METHOTREXATE IN SEVERE ALOPECIA AREATA, ALOPECIA TOTALIS, AND ALOPECIA UNIVERSALIS: A RANDOMIZED CONTROLLED TRIAL. Khyber Journal of Medical Sciences, 19(2). https://doi.org/10.70520/kjms.v19i2.880

Vancouver

Rehman H, Ullah G, Ajmal F, Rehman T, Naseer S, Rehman M. COMPARISON OF CLINICAL EFFICACY OF TOFACITINIB VERSUS METHOTREXATE IN SEVERE ALOPECIA AREATA, ALOPECIA TOTALIS, AND ALOPECIA UNIVERSALIS: A RANDOMIZED CONTROLLED TRIAL. Khyber Journal of Medical Sciences. 2026;19(2). doi:10.70520/kjms.v19i2.880

BibTeX
@article{Rehman2026,
  author = {Rehman, Hira and Ullah, Ghafoor and Ajmal, Filza and Rehman, Tooba and Naseer, Shahana and Rehman, Marwah},
  title = {COMPARISON OF CLINICAL EFFICACY OF TOFACITINIB VERSUS METHOTREXATE IN SEVERE ALOPECIA AREATA, ALOPECIA TOTALIS, AND ALOPECIA UNIVERSALIS: A RANDOMIZED CONTROLLED TRIAL},
  journal = {Khyber Journal of Medical Sciences},
  year = {2026},
  volume = {19},
  number = {2},
  doi = {10.70520/kjms.v19i2.880}
}
Kostenlos starten →